Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
$0.90
-3.2%
$0.97
$0.61
$10.59
$14.02M-0.151.13 million shs321,131 shs
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
$1.18
-1.7%
$1.28
$0.87
$2.55
$22.63M0.48218,876 shs81,503 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.33
+0.6%
$3.18
$2.57
$6.88
$20.45M0.639,036 shs1,803 shs
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
$0.29
-8.8%
$0.39
$8.05
$15.80
$2.25M0.053,129 shs655,028 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00%+15.77%-9.71%-7.00%-93.04%
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
0.00%0.00%-12.09%-3.23%+29.03%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%-4.31%-1.19%-10.30%-48.76%
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
0.00%-20.66%+29.48%-54.00%-97.47%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.1253 of 5 stars
3.55.00.00.00.01.70.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.3834 of 5 stars
0.03.00.00.00.01.70.6
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
0.00
N/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
3.00
Buy$8.50620.34% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest PWUP, ALLR, NAII, and CMMB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.00
(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/A$1.62 per shareN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/A$0.72 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$113.80M0.18N/AN/A$13.32 per share0.25
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$24.51MN/A0.00N/AN/AN/A-147.94%-90.33%8/4/2025 (Estimated)
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$13.94M-$0.76N/AN/AN/AN/A-106.70%-82.18%8/20/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.56%-10.34%-5.19%N/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A

Latest PWUP, ALLR, NAII, and CMMB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/13/2025Q1 2025
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
-$8.10-$0.25+$7.85-$0.25N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/AN/AN/AN/AN/A
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
N/A
2.66
2.66
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
N/A
5.33
5.33
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.51
1.35
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Allarity Therapeutics, Inc. stock logo
ALLR
Allarity Therapeutics
1015.08 million15.08 millionNot Optionable
Chemomab Therapeutics Ltd. Sponsored ADR stock logo
CMMB
Chemomab Therapeutics
2018.86 million16.61 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.89 millionNot Optionable
PowerUp Acquisition Corp. stock logo
PWUP
PowerUp Acquisition
N/A7.77 million4.04 millionNot Optionable

Recent News About These Companies

Aspire Biopharma, PowerUp Acquisition complete business combination
Aspire Biopharma announces public listing on Nasdaq
(PWUP) Technical Pivots with Risk Controls
PowerUp Acquisition Corp trading resumes
PowerUp Acquisition Corp trading halted, volatility trading pause
When (PWUP) Moves Investors should Listen
PowerUp Acquisition Corp. Cl A
How to Take Advantage of moves in (PWUP)
PWUP PowerUp Acquisition Corp.
How To Trade (PWUP)
When the Price of (PWUP) Talks, People Listen
(PWUPU) Investment Analysis

New MarketBeat Followers Over Time

Media Sentiment Over Time

Allarity Therapeutics stock logo

Allarity Therapeutics NASDAQ:ALLR

$0.90 -0.03 (-3.23%)
Closing price 04:00 PM Eastern
Extended Trading
$0.90 -0.01 (-0.56%)
As of 07:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Chemomab Therapeutics stock logo

Chemomab Therapeutics NASDAQ:CMMB

$1.18 -0.02 (-1.67%)
Closing price 03:59 PM Eastern
Extended Trading
$1.18 0.00 (0.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.33 +0.02 (+0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$3.34 +0.01 (+0.30%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

PowerUp Acquisition stock logo

PowerUp Acquisition NASDAQ:PWUP

$0.29 -0.03 (-8.78%)
As of 06/20/2025

PowerUp Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on video gaming, gaming adjacent, and metaverse businesses. PowerUp Acquisition Corp. was incorporated in 2021 and is based in New York, New York.